Table 5.
Causes of death of patients receiving BEAM conditioning regimen and autologous HCT for DLBCL during 2003–2017
| BEAM | R-BEAM | |
|---|---|---|
| Number of patients | 265 | 87 |
| Primary disease | 179 (68) | 48 (55) |
| Organ failure | 19 (7) | 4 (5) |
| Infection | 15 (6) | 6 (7) |
| Second malignancy | 12 (5) | 13 (15) |
| Idiopathic pneumonia syndrome/Acute respiratory distress syndrome | 5 (2) | 1 (1) |
| Hemorrhage | 4 (2) | 1 (1) |
| Graft-versus-host disease1 | 3 (1) | 1 (1) |
| Vascular | 1 (<1) | 1 (1) |
| Other2 | 2 (<1) | 2 (2) |
| Missing | 25 (9) | 10 (11) |
1
4 cases had subsequent allogeneic transplantation.
2
Other cause: BEAM: 1 progressive multifocal encephalopathy; 1 sudden death. R-BEAM: 2 accidental death.
3
Infection as secondary cause of death: BEAM: 13 (5); R-BEAM: 5 (6).
Abbreviations: BEAM: carmustine, etoposide, cytarabine and melphalan; R-BEAM: rituximab +BEAM; auto-HCT: autologous hematopoietic cell transplantation; DLBCL: diffuse large B cell lymphoma